Immunotherapy advances target cancer and autoimmune diseases

Medical researchers are expanding the application of immunotherapy beyond oncology. At the Yale School of Medicine, physician-scientists are conducting clinical trials using CAR-T (chimeric antigen receptor-T cell) therapy to treat autoimmune diseases such as lupus, multiple sclerosis, and scleroderma. The goal is to identify and eliminate the specific immune cells responsible for attacking the body’s own tissues, potentially resetting the disease rather than merely suppressing symptoms.

Simultaneously, advancements in cancer vaccines are showing significant promise. In a clinical trial at Johns Hopkins, a patient with stage 4 fibrolamellar carcinoma achieved full remission within five months of receiving an experimental vaccine. Unlike traditional chemotherapy, these vaccines train the immune system to recognize and destroy cancer cells, offering the potential for long-term protection. While CAR-T therapy carries risks such as cytokine release syndrome, both developments represent a shift toward using the body’s own immune system to combat complex diseases.